2018 IPO
Rubius Therapeutics Stock
Rubius is developing a new class of drugs, Red-Cell Therapeutics™,
Sign up today and learn more about Rubius Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Rubius Therapeutics Stock
VentureLabs has been creating breakthrough companies since 2000. It is the first institution dedicated to entrepreneurial innovation, where discovery, invention and entrepreneuring are performed simultaneously by a world-class team of scientists, innovators and professional entrepreneurs. VentureLabs innovates, invents, launches and builds startups through a unique, systematic approach that produces best-in-class companies based on in-house innovations. VentureLabs has started 35 life science and technology companies, including Joule Unlimited, Seres Therapeutics (NASDAQ: MCRB), Pronutria Biosciences, Symbiota and Moderna Therapeutics.
Investors
Flagship Pioneering
Tessera Therapeutics, Indigo, Codiak Biosciences, Rubius Therapeutics, Cygnal Therapeutics
Funding History
| December 2015 | $25.0M |
|---|---|
| June 2017 | $120M |
Management
Senior Vice President, Corporate Development
Nathan Dowden
Co-Founder and Chief Innovation Officer
Avak Kahvejian
Chief Scientific Officer
Robert J Deans
President
Torben Straight Nissen
Press
TechCrunch - Aug, 4 2018
Boston-area startups are on pace to overtake NYC venture totalsTechCrunch - Aug, 4 2018
India may become next restricted market for U.S. cloud providersEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
